Fall in Human Papillomavirus Prevalence Following a National Vaccination Program

Grants

Funding Acknowledgements

This work was supported by Australian National Health and Medical Research Council Project Grant [APP1007685] and Anti- Cancer Council for Victoria Grant in Aid [628754]. John Kaldor and Bette Liu are supported by Fellowships from the National Health and Medical Research Council.S. N. T. was an investigator on a national HPV prevalence study that received partial, equal, and unrestricted funding from CSL Biotherapies and GlaxoSmithKline (GSK). J. M. L. B. is an investigator on an Australian Research Council Linkage Grant, for which CSL Biotherapies is a partner organization. J. M. L. B. was also an investigator on a national HPV prevalence study that received partial, equal, and unrestricted funding from CSL Biotherapies and GSK. B. L. owns shares in Commonwealth Serum Laboratories, supplier of HPV vaccine in Australia. S. M. G. has received advisory board fees and grant support from CSL and GSK, and lecture and consultancy fees from Merck. S. M. G. also reports having previously owned stock in CSL. S. G. has received grant support from Merck and GSK to carry out clinical trials for HPV/cervical cancer vaccines, and she is a member of the Merck global advisory and scientific advisory boards. S. R. S. is or has been an investigator on several clinical trials evaluating GSK's HPV vaccine, and her institution has received funding to collect data for these studies. S. R. S.'s institution has also received honoraria for Advisory Board membership, and reimbursement for attendance at conferences to present clinical trials data from GSK Biologicals; and has received unrestricted research funds from GSK Australia and CSL. All other authors report no potential conflicts.